Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants

生物等效性 医学 最大值 药代动力学 置信区间 随机对照试验 泌尿科 内科学 药理学
作者
Xin Cindy Zhang,Yuki Otani,Christopher D. Payne,Nathan J. Morris,Laiyi Chua,Rodrigo Escobar,Sihe Wang,Galen Huaiqiu Shi
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
卷期号:42 (11): 5529-5546 被引量:1
标识
DOI:10.1007/s12325-025-03335-z
摘要

Mirikizumab, a humanized anti-interleukin-23p19 monoclonal antibody, is approved for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). Two phase 1, open-label, two-arm, randomized studies compared pharmacokinetics and safety of mirikizumab (200 mg, Study AMBW; 300 mg, Study AMBX) to establish bioequivalence. Mirikizumab was administered subcutaneously using an autoinjector or a prefilled syringe (PFS) as a single dose in healthy participants. Participants (male and female) were randomized 1:1 to mirikizumab by a PFS (reference) and an autoinjector (test). Participants were sub-randomized (1:1:1) to one of three injection sites (abdomen, arm, thigh) and stratified into one of three weight groups. Primary endpoints were maximum observed drug concentration ( C max ), and area under concentration versus time curves (time zero to infinity [AUC 0–∞ ]; time to last time point with measurable concentration [AUC 0– t last ]). Secondary objectives were safety and immunogenicity. In Study AMBW, 90% confidence intervals (CIs) for the ratios (autoinjector to PFS) of geometric least squares mean values for C max , AUC 0–∞ , and AUC 0– t last were within prespecified bioequivalence limits (0.80–1.25). Similar results were observed in Study AMBX, after administration of mirikizumab 300 mg, with bioequivalence achieved for AUC 0– t last and AUC 0–∞ , while the upper bound of the 90% CI of the geometric least squares mean ratio for C max was slightly above the bioequivalence upper threshold. Overall safety of mirikizumab was similar between devices in both studies. Immunogenicity was similar overall in Study AMBW, but slightly higher (autoinjector versus PFS) in Study AMBX. Mirikizumab administered by autoinjector or PFS was considered bioequivalent at the 200-mg UC maintenance dose and the 300-mg CD maintenance dose. Safety and immunogenicity profiles were comparable between autoinjector and PFS. Availability of an autoinjector option may be preferred by some patients and may help improve patient adherence to treatment. ClinicalTrials.gov NCT04607733; NCT05069896.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bl完成签到,获得积分10
刚刚
chenzhuod完成签到,获得积分10
1秒前
读书看报吃饭睡觉完成签到,获得积分10
1秒前
1秒前
大约在冬季完成签到,获得积分10
1秒前
斯文败类的应助被369ninja采纳,获得10
2秒前
星辰大海的应助被倬琸采纳,获得10
2秒前
深情安青的应助被snjxh采纳,获得10
3秒前
瀼瀼完成签到,获得积分10
3秒前
淦淦淦完成签到 ,获得积分10
3秒前
ml完成签到 ,获得积分10
3秒前
一氧化二氢完成签到,获得积分10
3秒前
小虫完成签到,获得积分10
3秒前
Helen完成签到,获得积分10
4秒前
安静怜雪完成签到,获得积分10
4秒前
刘较瘦完成签到,获得积分10
4秒前
好运爆彭完成签到,获得积分10
5秒前
樊小雾完成签到,获得积分10
5秒前
Qinzhiyuan1990完成签到 ,获得积分10
5秒前
爱科研的Z完成签到,获得积分10
6秒前
princesun083完成签到,获得积分10
6秒前
ZeKaWa的应助被发呆采纳,获得10
6秒前
玩命的灵安完成签到,获得积分10
6秒前
科研通AI65的应助被月九采纳,获得10
7秒前
7秒前
汉堡包的应助被完美的映秋采纳,获得30
7秒前
8秒前
zhugeliu完成签到,获得积分10
8秒前
skmksd完成签到,获得积分10
8秒前
QIEZI完成签到 ,获得积分10
8秒前
万能图书馆的应助被zzx采纳,获得10
8秒前
小虫发布了新的文献求助10
8秒前
科研通AI6.4的应助被长风入林采纳,获得10
9秒前
9秒前
点点完成签到 ,获得积分10
10秒前
satellite完成签到,获得积分10
10秒前
10秒前
11秒前
YuLu完成签到 ,获得积分10
12秒前
张颖涛完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039